Your account is not claimed yet. You can sign up with ORCID to claim your account.

Klaus Podar

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 10

Top Venues

Cancers

Leukemia

Clinical cancer research : an official journal of the American Association for Cancer Research

Breast cancer research and treatment

Karl Landsteiner University of Health Sciences

University of Vienna & Harvard Medical School (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Karl Landsteiner University of Health Sciences Sep 1o 2016

Austria

Consultant :: Department of Internal Medicine II

Education History

University of Vienna & Harvard Medical School

Austria

PHD :: Microbiology and Genetics & Medical Oncology

Publications

Stella Rosa Maria Wirth, Klaus Podar, Martin Pecherstorfer, Philipp Wohlfarth, Ulrich Jäger, Josef Singer
Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination-A Retrospective Cohort Study. Cancers 15 (2) (2023)
Stella Rosa Maria Wirth, Klaus Podar, Martin Pecherstorfer, Philipp Wohlfarth, Ulrich Jäger, Josef Singer
Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination-A Retrospective Cohort Study. Cancers 15 (2) (2023)
Lukas John, Maria Theresa Krauth, Klaus Podar, Marc-Steffen Raab
Pathway-Directed Therapy in Multiple Myeloma. Cancers 13 (7) (2021)
Fengjuan Fan, Klaus Podar
The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology. Cancers 13 (10) (2021)
Josef Singer, Nguyen-Son Le, Daniel Mattes, Valerie Klamminger, Klaus Hackner, Nicole Kolinsky, Michaela Scherb, Peter Errhalt, Gudrun Kreye, Martin Pecherstorfer, Sonia Vallet, Klaus Podar
Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients. Cancers 13 (17) (2021)
Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, Judith Lind, Jose Manuel Garcia-Manteiga, Eugenio Morelli, Qinyue Jiang, Anja Seckinger, Dirk Hose, Hartmut Goldschmidt, Andreas Stadlbauer, Chunyan Sun, Heng Mei, Martin Pecherstorfer, Latifa Bakiri, Erwin F Wagner, Giovanni Tonon, Martin Sattler, Han Yan, Pierfrancesco Tassone, Dirk Jaeger, Klaus Podar
JunB is a key regulator of multiple myeloma bone marrow angiogenesis. Leukemia 35 (12) (2021)
Klaus Podar, Xavier Leleu
Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. Cancers 13 (20) (2021)
Moshe Lapidot, Abigail E Case, Dalia Larios, Helen I Gandler, Chengcheng Meng, Isidora Tošić, Ellen L Weisberg, Michael J Poitras, Prafulla C Gokhale, Cloud P Paweletz, Klaus Podar, Ravi Salgia, Srinivas V Saladi, James D Griffin, David A Frank, Raphael Bueno, Martin Sattler
Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). Cancers 13 (1) (2020)
Andreas Stadlbauer, Thomas M Kinfe, Ilker Eyüpoglu, Max Zimmermann, Melitta Kitzwögerer, Klaus Podar, Michael Buchfelder, Gertraud Heinz, Stefan Oberndorfer, Franz Marhold
Tissue Hypoxia and Alterations in Microvascular Architecture Predict Glioblastoma Recurrence in Humans. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (6) (2020)
Sonia Vallet, Fengjuan Fan, Stefano Malvestiti, Martin Pecherstorfer, Martin Sattler, Andreas Schneeweiss, Henning Schulze-Bergkamen, Joseph T Opferman, Michael H Cardone, Dirk Jäger, Klaus Podar
Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer. Breast cancer research and treatment 173 (3) (2018)

Klaus Podar.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Klaus Podar